When Geneticists and Clinicians Mate, Outcomes Database
Executive Summary
Sequana's agreement with Memorial Sloan-Kettering Cancer Center to form a $10 million joint venture dedicated to cancer genetics is not unlike the genes it seeks to uncover-it is unique in both structure and function. The still unnamed company, willcorrelate the genotype information gathered from breast, colon, and prostrate cancer tissue samples with Sloan-Kettering's detailed data on the original diagnosis, treatment, and outcomes of these cancers.